Navigation Links
QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
Date:8/22/2007

Multicenter Study Enrolls More Than 800 Women to Evaluate QuatRx's

New-Generation Selective Estrogen Receptor Modulator (SERM)

ANN ARBOR, Mich., Aug. 22 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, today announced that it has completed enrollment of a pivotal Phase 3 clinical trial of Ophena(TM) (ospemifene), the company's estrogen-free oral therapy in development for the treatment of vaginal symptoms associated with menopause.

Ophena(TM) is a new-generation selective estrogen receptor modulator (SERM) for postmenopausal vaginal syndrome (PVS), a common condition in postmenopausal women sometimes referred to as vaginal atrophy and characterized by vaginal symptoms such as dryness, irritation and sexual pain. Phase 2 clinical trials with Ophena(TM) demonstrated beneficial effects on vaginal epithelium and bone markers. In addition, in a Phase 2 trial, Ophena(TM) did not induce hot flashes in postmenopausal women when compared to placebo.

Patient enrollment for the randomized, double-blind study has reached 827 post-menopausal women at 80 trial centers throughout the United States. Women participating in the study are treated with either a 30- or 60-mg once daily oral dose of Ophena(TM) or placebo for 12 weeks. The study is the first of two pivotal Phase 3 efficacy trials planned for the compound.

"Completion of enrollment for this first Ophena(TM) Phase 3 trial is a significant development milestone," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx. "In this pivotal study we are seeking to confirm the beneficial vaginal effects already seen in our Phase 2 program. Millions of women suffer from such post-menopausal symptoms for which there are no oral non-estrogen treatments available. Ophena(TM) is specifically designed to address a major unmet
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Celsion Completes Enrollment in Phase I Liver Cancer Study
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Monitoring Patient Glucose Levels: New Advances in software make it easier
6. Managing Preanalytical Processes for Patient Safety
7. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
8. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014  RedRick Technologies, a ... and reading room environment guidance, has helped the ... radiology reading room, which may also serve as ... Penn Medicine. "In line with ... College of Radiology,s Imaging 3.0 ™ initiative, ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Depomed, Inc. (NASDAQ: ... at the Piper Jaffray 26 th Annual Healthcare Conference in ... at the Piper Jaffray conference is scheduled for 8:00 am EST ... be webcast, and the webcast can be accessed via the Investor ... recording of the webcast will be archived for 30 days on ...
(Date:11/21/2014)... Texas , Nov. 21, 2014  Lexicon Pharmaceuticals, ... pricing of its previously announced underwritten public offering of ... an effective shelf registration statement. The offering will consist ... offering price of $1.005 per share.  Lexicon has also ... to 7,462,687 additional shares of common stock.  All of ...
Breaking Medicine Technology:RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3
... Surgical Company (Nasdaq: STAA ) today announced that it will release ... Monday, November 2, 2009 after the market close. ... webcast on Tuesday, November 3, 2009 at 10:00 a.m. Eastern ... the Company,s third quarter results and current corporate developments. The timing ...
... SAN DIEGO, Oct. 27 Orexigen® Therapeutics, Inc. (Nasdaq: ... (ITT) analyses from the COR-I and COR-II Phase 3 trials ... stage Orexigen candidates for the treatment of obesity. These ... findings from a panel discussion on Saturday where the Company ...
Cached Medicine Technology:STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call 2Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 2Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 3Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 4Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 5Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 6
(Date:11/22/2014)... 23, 2014 BambooFlooringChina.com is a ... has proudly released its new collection of bamboo mats ... up to 29% off. , According to the ... tree-like grass, making it a highly renewable resource. Their bamboo ... a mixing color which comes from natural bamboo with caramel ...
(Date:11/22/2014)... Setria® Glutathione is now available ... for use “as a therapeutically active ingredient in ... Therapeutic Goods (Listing) Notice 2014 (No. 5) - ... Glutathione will be exclusivity distributed in Australia by ... imports fine chemicals to Australian manufacturers. TGA approval ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Discount-Dress.com ... aim of the firm is to increase the company’s online ... introduced a new selection of bridesmaid dresses and announced a ... offer is valid until Dec. 30, 2014. All the dresses ... also inexpensive. , In fact, Discount-Dress.com is very good ...
(Date:11/22/2014)... Nocturia is defined by the International ... individual has to wake at night one or ... Pipeline Review, H2 2014” provides comprehensive information on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:11/22/2014)... A petition seeking a ban on ... in minimally-invasive hysterectomies and fibroid removal surgeries has gained ... October, Bernstein Liebhard LLP reports. According to Change.org, ... 21st, 2014. That represents an increase of 456 signatures ... to the campaign.* , The campaign to ban uterine ...
Breaking Medicine News(10 mins):Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4
... Society (CNS) invites members of the press to attend its ... the Palmer House Hotel. See the latest scientific research in ... and memory, the neurological processes that govern our eating habits, ... Highlights will include: , 75 scientific talks ...
... (HealthDay News) -- Children and teens who are overweight or ... peers, a new study finds. The strength of the ... The strongest association between body-mass index (BMI), a measure of ... found in Hispanic youth, while the link between being overweight ...
... Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- A ... Parkinson,s disease appears to speed recovery in traumatic brain ... injury (TBI) victims who weren,t fully conscious and were ... hydrochloride. The drug is already given "off-label" to such ...
... WEDNESDAY, Feb. 29 (HealthDay News) -- All children can benefit ... or poor families or from homes where parents don,t provide ... included 1,200 identical and fraternal twins from 600 families who ... age 5. Overall, children who went to preschool did ...
... of the immune cells targeted by HIV may play ... infection, potentially helping to determine how quickly infection will ... Translational Medicine , a team of researchers from the ... Harvard describe finding a population of HIV-specific CD4 T ...
... -- Scientists from Seattle Children,s Research Institute and the ... Group Nijmegen in the Netherlands, have identified two new ... that is characterized by droopy eyelids and intellectual disabilities. ... number of genes identified with this type of brain ...
Cached Medicine News:Health News:Obesity Linked to Asthma in Children 2Health News:Drug Seems to Speed Recovery After Traumatic Brain Injury 2Health News:Drug Seems to Speed Recovery After Traumatic Brain Injury 3Health News:Drug Seems to Speed Recovery After Traumatic Brain Injury 4Health News:Preschool Kids Best Prepared for Kindergarten: Study 2Health News:Ragon Institute study finds HIV-specific CD4 cells that control viral levels 2Health News:Ragon Institute study finds HIV-specific CD4 cells that control viral levels 3Health News:Study finds new genes that cause Baraitser-Winter syndrome, a brain malformation 2
... Products are kept in ... are offered as 1-piece ... or extra long lengths. ... insulation, flush ports, rotating ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
Medicine Products: